<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="57512">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02357342</url>
  </required_header>
  <id_info>
    <org_study_id>RKM008</org_study_id>
    <nct_id>NCT02357342</nct_id>
  </id_info>
  <brief_title>Sirolimus Versus AntiVEGF for Wet AMD</brief_title>
  <official_title>Sirolimus Versus AntiVEGF for Wet AMD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maturi, Raj K., M.D., P.C.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maturi, Raj K., M.D., P.C.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 2 clinical trial, single site, randomized, subject-masked study to determine safety
      and efficacy of intravitreal injections of Sirolimus in subjects with wet Age-Related
      Macular Degeneration (wet AMD) with persistent intraretinal or subretinal edema due to
      neovascular AMD despite previous Anti-VEGF treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Thirty subjects will be randomized to receive intravitreal Sirolimus or standard of care
      treatment in a 1:1 ratio. Over the course of the six month trial plus a 6 month optional
      extention, subjects will be evaluated monthly. Treatment with Sirolimus will be given at
      baseline, month 2 and month 4 with sham injections given at months 1, 3 and 5. For subjects
      in the extension Sirolimus will also be given at months 6, 8 and 10 with sham at month 7, 9,
      and 11. Subjects in the standard of care group will receive anti-VEGF injections or sham
      monthly. Retreatment criteria will be based upon continued subretinal edema, intraretinal
      edema or active chorioretinal neovascularization (CNV)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single Blind (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in edema from baseline to month 6 measured by central subfield thickness on Heidelberg optical coherence topography</measure>
    <time_frame>6 months</time_frame>
    <description>Change in edema from baseline to month 6 as measured by central subfield thickeness on Heidelberg optical coherence topography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>visual acuity (best corrected visual acuity)</measure>
    <time_frame>6 months</time_frame>
    <description>Change in best corrected visual acuity from baseline to month 6</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Age-Related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Sirolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravitreal Sirolimus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care intravitreal anti-VEGF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>anti-VEGF intravitreal injections</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
    <description>intravitreal injection</description>
    <arm_group_label>Sirolimus</arm_group_label>
    <other_name>DE-109</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard of Care intravitreal injections of anti-VEGF</intervention_name>
    <description>intravitreal injections of anti-VEGF</description>
    <arm_group_label>Standard of Care intravitreal anti-VEGF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  best corrected visual acuity of 5-65, inclusive, in study eye

          -  presence of choroid neovascularization secondary to AMD

          -  persistent edema despite at least 3 previous intravitreal anti-VEGF injections in the
             past 5 months

        Exclusion Criteria:

          -  greater than 100 micron decrease in central subfield thickness on OCT since last
             standard of care visit

          -  history of major ophthalmic surgery in the study eye in the past 3 months

          -  history of significant ocular disease or condition other than exudative AMD that may
             confound results
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raj K Maturi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Raj K. Maturi, MD, PC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Raj K Maturi MD PC</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46290</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 12, 2017</lastchanged_date>
  <firstreceived_date>February 2, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
